| Symbol | ABOS |
|---|---|
| Name | ACUMEN PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 427 PARK STREET, CHARLOTTESVILLE, Virginia, 22902, United States |
| Telephone | +1 434 297-1000 |
| Fax | — |
| — | |
| Website | https://www.acumenpharm.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimers disease. The companys lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Acumen Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001140361-26-013660 <b>Size:</b> 8 KB
Read moreNew Form EFFECT - Acumen Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 9999999995-26-001054 <b>Size:</b> 1 KB
Read moreNew Form 424B3 - Acumen Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001628280-26-022853 <b>Size:</b> 133 KB
Read moreNew Form S-3 - Acumen Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001628280-26-021442 <b>Size:</b> 433 KB
Read moreNew Form S-8 - Acumen Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001628280-26-021418 <b>Size:</b> 231 KB
Read more(30% Negative) ACUMEN PHARMACEUTICALS, INC. (ABOS) Reports Q1 2026 Financial Results
Read moreAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Read moreAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Read moreAcumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Read moreMeisner Derek M 🟡 adjusted position in 2.1K shares (1 derivative) of Acumen Pharmaceuticals, Inc. (ABOS) at $3.26 Transaction Date: Mar 06, 2026 | Filing ID: 016645
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07430202 | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonis… | Phase1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Not_Yet_Recruiting | 2026-05-01 | 2030-05-01 | ClinicalTrials.gov |
| NCT06511570 | A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug … | Phase1 | Alzheimer Disease | Completed | 2024-06-25 | 2024-09-17 | ClinicalTrials.gov |
| NCT06335173 | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participan… | Phase2 | Alzheimer Disease | Active_Not_Recruiting | 2024-02-29 | 2026-10-01 | ClinicalTrials.gov |
| NCT06027086 | DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With … | Phase1 | Fibrolamellar Hepatocellular Carcinoma | Recruiting | 2024-02-12 | 2033-09-01 | ClinicalTrials.gov |
| NCT05999435 | Study of LAU-7b for the Treatment of Long COVID in Adults | Phase2 | Long COVID | Completed | 2023-11-15 | 2024-11-30 | ClinicalTrials.gov |
| NCT04931459 | A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Par… | Phase1 | Alzheimer Disease | Completed | 2021-06-21 | 2023-06-12 | ClinicalTrials.gov |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Terminated | 2020-08-31 | 2023-03-28 | ClinicalTrials.gov |
| NCT04417257 | Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Diseas… | Phase2 | COVID-19 Disease | Terminated | 2020-08-18 | 2024-05-30 | ClinicalTrials.gov |
| NCT03265288 | Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults | Phase2 | Cystic Fibrosis | Completed | 2018-11-05 | 2021-09-15 | ClinicalTrials.gov |
| NCT01456611 | Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1% | Phase3 | Osteo Arthritis of the Knee | Completed | 2011-09-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01372423 | Evaluation of Clinical Equivalence Between Two Lubiprostone Products | Phase3 | Chronic Idiopathic Constipation | Completed | 2011-05-01 | 2012-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Diclofenac | DRUG | Phase PHASE3 | Osteo Arthritis of the Knee | COMPLETED | NCT01456611 |
| Lubiprostone | DRUG | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01372423 |
| atezolizumab | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04471415 |
| Placebo oral capsule | DRUG | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT03265288 |
| LAU-7b | DRUG | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT03265288 |
| Placebo for 3 cycles | OTHER | Phase PHASE2 | Long COVID | COMPLETED | NCT05999435 |
| LAU-7b for 1 cycle, then placebo | DRUG | Phase PHASE2 | Long COVID | COMPLETED | NCT05999435 |
| LAU-7b for 3 cycles | DRUG | Phase PHASE2 | Long COVID | COMPLETED | NCT05999435 |
| Durvalumab | DRUG | Phase PHASE1 | Fibrolamellar Hepatocellular Carcinoma | RECRUITING | NCT06027086 |
| Ipilimumab | DRUG | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Nivolumab | DRUG | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| DRP-104 | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04471415 |
| DNAJB1-PRKACA Peptide Vaccine | DRUG | Phase PHASE1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | NOT_YET_RECRUITING | NCT07430202 |
| Placebo | DRUG | Phase PHASE3 | Osteo Arthritis of the Knee | COMPLETED | NCT01456611 |